Scheme 1. Conversion of the Masked p-Benzoquinone 1 to
Ketone 3
utility. Compound 1 (Scheme 1) is a p-benzoquinone equiva-
lent, with one of the carbonyl groups protected by ketalization
and one of the carbon-carbon double bonds masked by
addition of thiophenol. The racemate of 1 is easily available,
and its chromatographic resolution can be efficiently per-
formed.7 The absolute configuration of (+)- and (-)-1 was
unequivocally established by chemical correlation.8 Treat-
ment of 1 with NaBH4 exclusively furnishes the cis alcohol
2, which can be converted to ketone 3 in good overall yield.8,9
We visualized ketone 3 as a very suitable starting material
to undertake a systematic synthesis of gabosines and other
related compounds through the strategy depicted in Scheme
2, which involves three main transformations: (i) alkylation
Figure 1. Gabosine family of secondary metabolites: structural
classification.
Scheme 2. Diversity-Oriented Synthetic Strategy to Gabosines
and Related Compounds
antibiotic KD16-U1 and its crotonyl ester, named COTC, is
a potent glyoxylase-I inhibitor that is potentially cytotoxic.4,5
Gabosine E is a weak inhibitor of cholesterol biosynthe-
sis,1b and the antibacterial activity1a and DNA-binding
properties1d of several gabosines have also been described.
Their peculiar structure and promising biological activity
have motivated synthetic studies directed at these targets.
As a result, syntheses of several gabosines have already been
accomplished,6 but a synthetic strategy suitable for a large
number of these compounds from common synthetic inter-
mediates has not been described hitherto. We have designed
a rational, diversity-oriented approach to these compounds,
completed the synthesis of each enantiomer of gabosines O
and N and their C4 epimers, and established the previously
unknown absolute configuration of natural gabosine O. These
studies are described herein.
In previous investigations, we prepared a series of chiral
p-benzoquinone derivatives and explored their synthetic
(4) Chimura, H.; Nakamura, H.; Takita, T.; Takeuchi, T.; Umezawa,
H.; Kato, K.; Saito, S.; Tomisawa, T.; Iitaka, Y. J. Antibiot. 1975, 28, 743.
(5) ) Sugimoto, Y.; Suzuki, H.; Yamaki, H.; Nishimura, T.; Tanaka, N.
J. Antibiot. 1982, 35, 1222.
of the doubly activated C6 position of 3 to introduce the
methyl or hydroxymethyl substituent; (ii) dihydroxylation
or epoxidation of the double bond to provide the cis or trans
C2-C3 glycol unit, respectively; and (iii) reduction of the
C6-S bond or oxidation to the sulfoxide followed by
(6) Gabosines ent-C and E: (a) Lygo, B.; Swiatyj, M.; Trabsa, H.; Voyle,
M. Tetrahedron Lett. 1994, 35, 4197; gabosine C and COTC: (b) Tatsuta,
K.; Yasuda, S.; Araki, N.; Takahashi, M.; Kamiya, Y. Tetrahedron Lett.
1998, 39, 401. (c) Huntley, C. F. M.; Wood, H. B.; Ganem, B. Tetrahedron
Lett. 2000, 41, 2031. (d) Takahashi, T.; Yamakoshi, Y.; Okayama, K.;
Yamada, J.; Ge, W.-Y.; Koizumi, T. Heterocycles 2002, 56, 209. (e)
Ramana, G. V.; Rao, B. V. Tetrahedron Lett. 2005, 46, 3049. Gabosine I:
ref 3. (()-Gabosine B and putative structure of (()-gabosine K: ref 1c.
Gabosine A: (f) Banwell, M. G.; Bray, A. M.; Wong, D. J. New J. Chem.
2001, 25, 1351. Gabosines A, B, ent-D, and ent-E: (g) Shinada, T.; Fuji,
T.; Ohtani, Y.; Yoshida, Y.; Ohfune, Y. Synlett 2002, 1341.
(7) (a) de March, P.; Escoda, M.; Figueredo, M.; Font, J. Tetrahedron
Lett. 1995, 36, 8665. (b) de March, P.; Escoda, M.; Figueredo, M.; Font,
J.; Medrano, J. An. Quim. Int. Ed. 1997, 93, 81.
(8) de March, P.; Escoda, M.; Figueredo, M.; Font, J.; Garc´ıa-Garc´ıa,
E.; Rodr´ıguez, S. Tetrahedron: Asymmetry 2000, 15, 4473.
1618
Org. Lett., Vol. 8, No. 8, 2006